Intellia Therapeutics

Intellia Therapeutics is a clinical-stage biotechnology company pioneering the development of CRISPR-based genome editing therapies for the treatment of genetic diseases. Its business model centers on advancing both in vivo and ex vivo gene editing programs, with lead candidates targeting conditions such as transthyretin amyloidosis and hereditary angioedema. Intellia is recognized as a leader in the gene editing field, collaborating with major biopharmaceutical partners to expand its therapeutic pipeline.

Company Facts

• Headquarters: Cambridge, United States
• Founded: 2014
• Employees: 526
• Type: Public Corporation
• Website: https://www.intelliatx.com
• Industries: Biotechnology, Genomics, Pharmaceuticals, Life Sciences